Sechenov School
Home › Microbiology › Clinical Presentation of HIV Infection

Clinical Presentation of HIV Infection

Human immunodeficiency virus

For medical students2 min readUpdated 2026-10-10

The clinical picture of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) is driven not by the direct cytopathic effect of the virus, but by the development of severe opportunistic infections and malignancies resulting from the destruction of the immune system. The disease progresses through distinct stages—from asymptomatic carriage to irreversible terminal conditions.

Seronegative WindowThe period during which antibodies are absent averages 3 months, but can extend to 6–10 months.
Early MarkerThe p24 antigen is detectable in blood via ELISA as early as 1–2 weeks post-infection.
Viral MutationsThe pathogen continuously generates new "quasispecies," preventing the development of sterilizing immunity.
AIDS PrognosisA sharp drop in antibody titers against the p24 protein indicates progression to the terminal stage.

Dynamics of the Immune Response and Serological Markers

The immune response during HIV infection follows a distinct timeline from primary contact with the pathogen to full-blown AIDS.

Immediately after infection, the seronegative window period begins. During this time, specific antibodies against the virus are completely absent from the blood. On average, this stage lasts about 3 months, though it can vary from 2 weeks to 6–10 months depending on individual host reactivity.

The primary diagnostic marker during this early window is the viral p24 antigen. Using enzyme-linked immunosorbent assay (ELISA), it can be detected as early as 1–2 weeks post-infection. This protein circulates in the bloodstream until approximately the 8th week, after which its concentration drops sharply. Notably, a secondary massive surge in p24 levels occurs only in the terminal stage of the disease.

This is followed by seroconversion: the p24 antigen disappears, and specific immunoglobulins begin to be produced.

Falling p24 antibody titers carry significant prognostic value—they directly correlate with the progression of the infection to AIDS.

Importantly, protective (sterilizing) immunity against the pathogen does not develop. Although antibodies are produced, their neutralizing activity remains extremely low. This is due to the high mutation rate of the virus: it continuously alters its structure, generating new variants ("quasispecies") and successfully evading immune surveillance.

Clinical Staging Classification

Clinical management often utilizes a standardized staging classification of the infectious process that reflects the gradual progression of immunodeficiency:

  1. Incubation Period. Measured from the moment of viral entry until the appearance of acute infection symptoms or the onset of antibody production. Lasts from 3 weeks to 3 months.
  2. Primary Manifestations Stage. Symptoms of acute viral infection appear alongside seroconversion. This phase lasts approximately 1 year.
  3. Subclinical Stage. Characterized by a slow, latent progression of immunodeficiency. Obvious clinical symptoms are absent. This is the longest stage, lasting about 6–7 years.
  4. Secondary Diseases Stage. Immunodeficiency reaches clinically significant levels, leading to the onset of severe secondary pathologies. This phase typically culminates 10–12 years after initial infection.
  5. Terminal Stage (AIDS). Characterized by severe, entirely irreversible secondary conditions that ultimately lead to patient mortality.

AIDS-Defining and Opportunistic Diseases

The primary clinical feature of HIV is that the symptoms themselves are not directly caused by the immunodeficiency virus. Instead, the severe clinical picture results from opportunistic infections occurring against a background of critically suppressed immunity.

Typical pathogens affecting patients in late stages include:

In the full-blown AIDS stage, so-called AIDS-defining illnesses develop, the presence of which directly indicates terminal immunodeficiency. Infectious complications include viral infections (severe herpesvirus infections, viral hepatitis B and C), bacterial infections (active tuberculosis, salmonellosis, various atypical mycobacterioses), and protozoal infections (cerebral toxoplasmosis). Malignancies occupy a special place: Kaposi sarcoma and various malignant lymphomas are highly specific to the AIDS stage. Severe nervous system disorders presenting with diverse neurological manifestations are also characteristic.

Mnemonic

To quickly remember the staging stages, use the mnemonic I-P-S-S-T: Incubation, Primary manifestations, Subclinical, Secondary diseases, Terminal.

Frequently asked questions

Which pathogens cause severe opportunistic infections in late-stage HIV?

In late-stage HIV infection, severe opportunistic diseases are caused by protozoa, viruses, bacteria, and fungi. Typical pathogens include:

  • Pneumocystis (Pneumocystis jirovecii) — causes Pneumocystis pneumonia.
  • Toxoplasma — leads to CNS involvement (toxoplasmosis).
  • Cryptosporidia — cause intestinal infections (cryptosporidiosis).
  • Cytomegalovirus — causes generalized infection with multiorgan involvement (retinitis, pneumonia, encephalitis).
  • Fungi — cause candidiasis and histoplasmosis.

Herpes viruses, hepatitis B and C viruses, mycobacteria (tuberculosis, mycobacteriosis), and salmonellae also play a significant role.

Which immune cells are the primary targets for the human immunodeficiency virus?

The primary targets for HIV are cells bearing the CD4 receptor on their surface. These include:

  • T-helper cells — activated CD4+ T-lymphocytes (primarily Th1 and Th2 subsets), which undergo apoptosis or lysis upon viral interaction.
  • Macrophages — tissue macrophages and monocytes, which resist destruction and serve as a viral reservoir.
  • Myeloid dendritic cells and Langerhans cells — act as carriers and reservoirs of the virus.
  • Microglial cells — neuroglial cells that also undergo the cytopathic effects of the virus.
Which enzymes are contained within the HIV virion core to ensure its replication?

The core (nucleocapsid) of the HIV virion contains a complex of enzymes encoded by the pol gene that ensure viral replication. These include:

  • Reverse transcriptase — an RNA-dependent DNA polymerase that synthesizes complementary DNA using viral RNA as a template.
  • Integrase — facilitates the integration of the synthesized viral DNA into the host cell chromosome.
  • Protease — part of the capsid enzyme complex involved in processing viral proteins during replication.
What are the main routes of transmission for HIV?

HIV is transmitted through three main routes:

  • Sexual route — transmission occurs via unprotected heterosexual and homosexual contact.
  • Blood-borne (hematogenous) route — injection and parenteral exposure via intravenous drug use, blood transfusions, organ and tissue transplants, and the use of non-sterile medical instruments.
  • Vertical route — transmission from an infected mother to her child during pregnancy (transplacentally), during labor and delivery, or via breastfeeding.
Why do antibodies in HIV infection fail to protect against disease progression?

The virus constantly mutates within the host, generating new structural variants known as "quasispecies." Consequently, the produced antibodies exhibit low neutralizing activity and cannot establish sterilizing immunity.

How does the p24 marker behave during different stages of infection?

The p24 antigen appears within the first 1–2 weeks post-infection, and its level drops sharply by week 8. A second high surge of this protein is observed only in the terminal stage (AIDS).

What is the direct cause of symptoms during the AIDS stage?

The virus itself does not cause a distinct primary clinical syndrome at late stages. All severe manifestations are driven by opportunistic infections (e.g., pneumocystosis, toxoplasmosis) and malignancies (e.g., Kaposi sarcoma, lymphomas) arising from immune destruction.

Go deeper

More topics in Microbiology

Relapsing FeversChlamydophila pneumoniae: Pathogen of Respiratory ChlamydiosisPathogenesis and Clinical Features of InfluenzaRespiratory Syncytial VirusHepatitis A VirusDNA Oncogenic Viruses: Mechanism of TransformationJapanese Encephalitis VirusTrichophytosis: Types, Pathogens and MorphologyParacoccidioidomycosisPenicilliosis (Penicillium)TrichomonasIsospora: Anatomy, Lifecycle and Clinical FeaturesMicrobiology →